Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;74(2):131-142.
doi: 10.1002/iub.2559. Epub 2021 Sep 30.

SHP2: The protein tyrosine phosphatase involved in chronic pulmonary inflammation and fibrosis

Chun-Jung Chang  1   2 , Chiou-Feng Lin  3   4 , Bing-Chang Chen  1 , Pei-Yun Lin  1 , Chia-Ling Chen  1   5
Affiliations
Free article
Review

SHP2: The protein tyrosine phosphatase involved in chronic pulmonary inflammation and fibrosis

Chun-Jung Chang et al. IUBMB Life. 2022 Feb.
Free article

Abstract

Chronic respiratory diseases (CRDs), including pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), lung cancer, and asthma, are significant global health problems due to their prevalence and rising incidence. The roles of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs) in controlling tyrosine phosphorylation of targeting proteins modulate multiple physiological cellular responses and contribute to the pathogenesis of CRDs. Src homology-2 domain-containing PTP2 (SHP2) plays a pivotal role in modulating downstream growth factor receptor signaling and cytoplasmic PTKs, including MAPK/ERK, PI3K/AKT, and JAK/STAT pathways, to regulate cell survival and proliferation. In addition, SHP2 mutation and activation are commonly implicated in tumorigenesis. However, little is known about SHP2 in chronic pulmonary inflammation and fibrosis. This review discusses the potential involvement of SHP2 deregulation in chronic pulmonary inflammation and fibrosis, as well as the therapeutic effects of targeting SHP2 in CRDs.

Keywords: CRDs; SHP2; fibrosis; inflammation.

PubMed Disclaimer

References

REFERENCES

    1. Xie M, Liu X, Cao X, Guo M, Li X. Trends in prevalence and incidence of chronic respiratory diseases from 1990 to 2017. Respir Res. 2020;21(1):49.
    1. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med. 2011;208(7):1339-1350.
    1. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378(19):1811-1823.
    1. Glass DS, Grossfeld D, Renna HA, et al. Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches. Respir Investig. 2020;58(5):320-335.
    1. Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: The myofibroblast in focus. Chest. 2007;132(4):1311-1321.

Publication types

MeSH terms

Substances

LinkOut - more resources